Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Fig 1.Management of the axilla for patients with clinical T ≤2 cm breast cancer. a Multidisciplinary discussion of adjuvant therapy options should occur prior to surgery when omitting sentinel lymph ...

Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic ...

PCS involves extensive surgical effort to achieve optimal debulking, defined as no residual tumor or minimal residual disease. This approach has been associated with improved survival rates when ...

The purpose of this clinical practice guideline is to provide referring and imaging clinicians (including medical oncologists, radiation oncologists, urologists, radiologists, nuclear medicine ...

ASCO–Society for Integrative Oncology (SIO) Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline ...

Axillary staging for breast cancer has been a standard part of initial surgical treatment since 2002 when Fisher et al published the National Surgical Adjuvant Breast and Bowel Project (NSABP) B06, 1 ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included ...